- Home
- / embecta
embecta
Stock Price
$14.5
2024-10-29
Market Capitalization
$834.9 M
2024-10-29
Revenue
$1.1 B
FY, 2025
embecta Summary
Company Summary
- Overview
- embecta (formerly part of BD) is a medtech company focused on providing solutions for diabetes. It offers pen needles, insulin syringes, diabetes care app, and accessories.
- Type
- Public
- Status
- Active
- Founded
- 2022
- HQ
- Parsippany, NJ, US | view all locations
- Website
- https://www.embecta.com/
- Cybersecurity rating
Table of Contents
Key People
Ginny Blocki, SVP of Global Marketing & Product Management
Tom Blount, SVP, President - North America
Jean Casner, SVP, Chief Human Resources Officer
Operating MetricsView all
Trademark Applications
200
9.1%
FY, 2023
Trademarks
250
37.5%
FY, 2023
Countries
100
FY, 2023
LocationsView all
43 locations detected
Parsippany, NJ HQ
United States
300 Kimball Drive, Suite 300
Bismarck, ND
United States
120 W Sweet Ave
Boston, MA
United States
155 Federal Street, Suite 700
Franklin Lakes, NJ
United States
Howe Buidling, 1 Becton Dr
Lincoln, NE
United States
5601 S 59th Street
Montgomery, AL
United States
2 North Jackson Street, Suite 605
embecta Financials
Summary Financials
- Revenue (Q2, 2026)
- $221.8M
- Gross profit (Q2, 2026)
- $127.8M
- Cash (Q2, 2026)
- $184.9M
- EBIT (Q2, 2026)
- $35.0M
- Enterprise value
- $2.0B